European healthcare investment firm ArchiMed completed the acquisition of a majority stake in Namsa, a medical device testing company. Financial terms were not disclosed. Namsa chose ArchiMed in part because of its knowledge of the European market, one of the areas where Namsa hopes to expand. The deal is expected to close in September.